Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)
We are very excited to announce that Nanthini Tharahan from the Princes Margaret Clinical Trials Support Unit has received the inaugural Excellence in Clinical Trials Conduct Award at the CCTG Spring Meeting. This award is presented to an individual who exemplifies excellence in clinical trial operations or compliance at their institution.
“I would like to express my sincere thanks for the award.”
CCTG IND243: A Phase II Study of RP-6306 in Patients with Advanced Cancer has been centrally activated.
This study is being done to answer the following questions:
Request an invitation portal: closes April 17th
Online Registration: closes April 19th
On-site Registration: Beat the Friday morning line-up and register on Thursday!!
New this year at the CCTG Spring Meeting is an open workshop and education session on engaging patient representatives in CCTG clinical trials. This accredited workshop takes place on Friday 28 at 10:30 in the Wren room at the Chelsea Hotel.
Participants are invited to discuss and assess the Investigator and Patient perspective in patient-centred clinical trials. There will be an exploration of the CCTG Patient Engagement Model and an assessment of the clinical trial lifecycle identifying touch points to engage patients.
To ensure the security and safety of National Cancer Institute (NCI) systems, subjects, research staff, and all associated sensitive information, NCI introduced an identity verification system to access to the Cancer Therapy Evaluation Program (CTEP) and the Cancer Trails Support Unit (CTSU) websites in accordance with the Federal Information Security Management Act(FISMA) in July 2022. This new process uses ID.me, and requires completion of Identity Proofing (IP) and establishment of a Multi Factor Authentication (MFA) method as part of the registration process.